Progression of impending central retinal vein occlusion to the ischemic variant following intravitreal bevacizumab.
A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluorescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improvement over the following several months.
Kim
Na Rae
NR
Department of Ophthalmology, Inha University School of Medicine, #7-206, Shinheung-dong, Jung-gu, Incheon, Korea.
Chin
Hee Seung
HS
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018450:Disease Progression; D005260:Female; D005451:Fluorescein Angiography; D015355:Glaucoma, Neovascular / Q000150:complications; D006801:Humans; D056965:Injections, Intraocular; D007511:Ischemia / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab